Although the world now has a number of vaccines in place and available to serve as a preventative and/or impact-reduction method for COVID, there are a number of reasons that it is also important for the Pharma and Biopharma industries to continue developing other treatment and medicines to for those who become infected - with or without having taken the vaccine. Lucky for all of us, there are a few small molecule agents coming available for COVID patients in 2022, and during episode 51 of "The Weekly Bioanalysis", John and Dom discuss all the small molecule drugs being developed to meet these needs.

"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Twice every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. The Weekly Bioanalysis is brought to you by KCAS.

KCAS is a progressive growing contract research organization of well over 150 talented and dedicated individuals committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.